Dermal Filler Treatments Explained: What’s in the Syringe, How Long It Lasts, and How to Choose a Practitioner

By the Cosmabl Clinical Editorial Team. Medically reviewed by Dr Patrick Shively, Medical Director, AHPRA MED0001794908.

Last reviewed 2026-05-18 • Next review 2027-05-18

Dermal filler is the most-searched cosmetic injectable category in Australia, and arguably the most-misunderstood. Grand View Research sized the Australian facial-injectable market at USD $410.6 million in 2024, with hyaluronic acid filler accounting for the majority of that volume. Outpatient procedure counts have grown steadily for a decade. The product is medically well-characterised, the technique is well-described, and the on-label uses are broadly evidence-supported.

What is less well-explained — because it does not sell anything — is the chemistry of what actually goes under your skin, how long it really lasts (the answer has changed substantially in the last two years), and what the side-effect numbers are when you look at the published data rather than the brochure. Most of the clinic marketing in this category continues to describe fillers in language the 2024 literature has now contradicted.

This piece describes what is in a dermal filler syringe, what the chemistry does to your tissues, what the published evidence supports on duration, the side-effect rates a patient is entitled to know, and what the September 2025 AHPRA cosmetic guidelines and the TGA’s tightened advertising stance now require of every practitioner offering treatment.

What exactly is dermal filler

Chemistry tells you most of what you need to know about a filler. Three product families dominate the Australian market, and they behave differently enough in tissue that treating them as interchangeable is the first mistake a patient can make.

Hyaluronic acid is a sugar molecule your body already makes. For injectable cosmetic use it is crosslinked into a gel of varying density.

Different hyaluronic acid filler products vary in gel particle size, crosslinking method, and concentration. These differences shift how the gel handles in tissue: a soft, ribbon-like product suits lips and the tear-trough; a firm, structural product is built for jawline and chin. A practitioner choosing between them is making a clinical decision about anatomy and indication, not a quality judgement.

Calcium hydroxyapatite is composed of microspheres of a bone-mineral compound suspended in a gel carrier. The gel carrier provides immediate volume on the day; the microspheres remain in tissue and trigger a low-grade collagen response around them, which builds over months. Effects typically last 12 to 18 months. Calcium hydroxyapatite is not reversible with hyaluronidase. If you need it removed, your options are time, dilution, aspiration, or surgical intervention.

Poly-L-lactic acid does not really behave like a filler at all. It is a biostimulator: the gel dissipates within days, but the product provokes your own fibroblasts into producing collagen, which is what creates the gradual volume increase over the following months. Typical treatment regimens include series of three sessions 4-6 weeks apart, and results can last 18 to 36 months once the collagen is built. Like calcium hydroxyapatite, it is not enzymatically reversible.

Polymethyl methacrylate is the outlier: permanent microspheres in a collagen carrier, used in few indications, not removable by any means. Most Australian practitioners use it sparingly if at all, and many decline to use it at all.

How long do dermal fillers actually last — and the 2024 finding that changed the answer

For two decades the conventional answer to this question has been 6 to 12 months for lips, 12 to 18 months for cheeks and jawline. That answer is incomplete, and the patient asking it deserves the longer version. Duration can be thought of as the duration of visible effects and duration of physical persistence.

The duration of visible effects, which is what most patients mean when they ask “how long does the product last”, does roughly match the conventional figures. Lips turn over fastest, often visibly fading at 6 to 9 months because the muscle never stops moving. Nasolabial folds typically hold 9 to 12 months. Mid-face and cheek augmentation settles into a 12 to 18 month window in most patients. Structural zones like the jawline and chin can outlast that.

The duration of physical persistence is different, and considerably longer. A 2024 study by Master and colleagues in “Plastic and Reconstructive Surgery Global Open” used MRI to image the mid-face of 33 patients who had received hyaluronic acid filler 2 to 15 years previously. Filler signal was detectable in every single patient. None showed complete dissipation. A 2025 systematic review by de Castro Costa and colleagues in “Aesthetic Plastic Surgery” corroborated this with ultrasound data showing 12 to 36 months of measurable persistence as a routine finding and noted that one crosslinking technology specifically was associated with more long-term adverse events.

The clinical implication is straightforward. Filler does not metabolise and disappear on the timeline the marketing has been claiming for years. What fades visibly is the volumising effect; the gel itself remains in tissue, often for years longer than the patient or the practitioner has assumed. For a patient who has been having mid-face filler every nine to twelve months for a decade, the cumulative volume sitting in tissue is real, it is imageable, and it is part of why some long-term filler patients develop the diffuse over-volumisation that the 2024 “Journal of Cosmetic Dermatology” paper named as “facial overfilled syndrome” — a presentation the authors described as underdiagnosed and driven by repeated mismatched filler placement, where no single session would have been identified as wrong.

This is the conversation almost nobody is having on the patient-facing side. The conservative implication is that the gap between treatments, particularly in the mid-face, should be longer than the marketing typically suggests, and that the practitioner you want is one who will tell you to skip a year when your face does not need topping up. A clinic that books you in at twelve months by reflex is operating from outdated science.

How dermal filler treatment actually works

A standard appointment is more involved than most patients expect. The consultation portion — history-taking, assessment, photography, consent — is where the clinical work happens. The injection portion is usually the shortest part of the visit.

After cleansing the practitioner marks the treatment area, often with the patient sitting upright so resting facial position can be assessed. Topical anaesthetic may be applied; many modern hyaluronic acid products are formulated with lignocaine already mixed into the gel, which reduces injection discomfort meaningfully. For larger structural treatments or particularly sensitive areas, a dental block or infiltration anaesthetic may be used.

Injection technique varies by zone and by product. A blunt-tipped cannula is preferred in vascular high-risk areas — the glabella, the nose, the nasolabial folds, the temples — because it pushes vessels aside rather than piercing them. A sharp needle is faster and gives finer control in specific small-area work. The 2025 “Cureus” systematic review on vascular complications recommended slow retrograde injection, repeated aspiration before depositing product, and cannula use in high-risk zones as the three technique factors most strongly associated with avoiding complications.

After injection, the practitioner massages the product to distribute it evenly, photographs the result, and reviews aftercare with the patient. A reasonable appointment takes 45 to 75 minutes including consultation and post-procedure observation. An appointment that takes 20 minutes is one in which something has been skipped, usually the consultation or the consent.

Most patients can return to non-strenuous activity the same day. Swelling and bruising peak at 24 to 72 hours and usually settle inside a week. A review at two weeks is standard practice; this is when small touch-ups, if needed, can be performed and when any unevenness can be addressed before it sets.

Side effects, in numbers

Dermal filler is generally safe when administered by an experienced practitioner using a TGA-registered product in an appropriate clinical setting. “Generally safe” is not the same as “risk-free,” and the patient deserves the numbers in plain language.

Common adverse events are local and short-lived. Swelling occurs in roughly 78% of treatments. Firmness or palpable lumpiness in the first week occurs in around 48%. Bruising in 34%. Tenderness in 33%. These are pooled figures from a 2025 “Aesthetic Surgery Journal” meta-analysis of hyaluronic acid lip filler trials, and the rates outside lips are similar or slightly lower. Most of these resolve within two weeks without intervention. Patient-reported satisfaction across the same meta-analysis sat at 68% overall, with 82% reporting an improved aesthetic appearance.

Serious adverse events — defined as those requiring active treatment, follow-up, or persistence beyond a month — affected approximately 1.5% of patients in pooled data. Real, but not the headline figure.

Vascular occlusion is the complication every reputable filler injector trains for. It happens when filler enters or compresses a blood vessel and obstructs blood supply downstream. The 2025 “Cureus” systematic review by Chakhachiro and Waseem placed the per-treatment incidence at 0.01% to 0.05% across pooled studies. A 2025 retrospective series in “Plastic and Reconstructive Surgery” of 290,307 hyaluronic acid cases reported severe complications at 0.0041%.

These figures are reassuring at scale. The same “Cureus” review identified the central face — the glabella, the nose, the nasolabial folds — as the highest-risk anatomical zones because the facial artery and ophthalmic artery pass through them. Recovery from a vascular occlusion depends almost entirely on speed of recognition. Hyaluronidase given inside the first few hours has an 84.2% partial or total recovery rate; delays beyond five days correlate strongly with permanent damage. The window matters.

Vision loss from filler is the worst-case version of this. A 2024 PubMed update on filler-related blindness identified around 365 published cases of partial or complete vision loss. Where outcomes were tracked, approximately 70% of patients had no improvement despite intervention. The highest-risk anatomical zones for vision loss were the nose (40.6% of cases), the forehead (27.7%), and the glabella (19.0%). The absolute risk per treatment is extremely small and the published number is built over decades of global practice. But it is not zero, and any honest consent conversation for treatment in those zones should acknowledge this risk.

Other risks worth knowing. Late-onset nodules and granulomas can appear months or years after treatment, particularly with non-hyaluronic-acid fillers, and the 2024 Polish systematic review in “Dermatology Review” noted cases of filler-related cellulitis emerging up to 2.5 years post-injection. Migration of filler product is most reported in the lips and the tear-trough zone.

After any injectable cosmetic treatment, patients should contact their practitioner urgently if they experience sudden severe pain disproportionate to expected recovery, visual disturbance, blanching or mottling of the skin near the treatment area, fever, or rapidly spreading swelling. These symptoms can indicate vascular compromise and the window for effective intervention is measured in hours, not days.

What dermal filler treatments cost, and how to think about it

Australian cosmetic clinics generally price dermal filler one of two ways: per millilitre of product, or per treatment area. Per-millilitre pricing in published clinic ranges runs roughly AUD $600 to $1,200 per ml depending on the product family, the practitioner, and the city. Calcium hydroxyapatite and poly-L-lactic acid sit at the higher end of those ranges. Per-area pricing tends to be quoted as a flat fee for a defined zone — lips, chin, jawline — and typically runs AUD $600 to $1,800 per area depending on the volume needed.

Per-millilitre pricing is the more honest model because it ties what you pay to the dose you actually receive. Per-area pricing can quietly incentivise the clinic to use less product in each area, since the practitioner is paid the same regardless. A patient on per-area pricing whose result fades unusually quickly is entitled to know exactly how much product was used in their treatment; the answer is recorded in the clinical note and there is no good reason to withhold it.

Cumulative cost matters as much as per-visit cost, and is rarely discussed. A patient on a conservative three-yearly mid-face maintenance schedule, at AUD $1,500 per visit, spends around AUD $500 a year amortised. A patient on an annual every-zone protocol with a clinic that recommends multiple syringes per visit can spend many multiples of that. Given what the 2024 MRI data shows about filler persistence, the longer-interval approach is now more defensible on clinical grounds than it was when the field believed filler dissipated inside twelve months.

Cosmabl does not publish per-treatment prices for cosmetic injectables. The TGA’s updated advertising guidance, reinforced in June 2025, restricts price-based promotion of Schedule 4 cosmetic medicines, and the September 2025 AHPRA cosmetic guidelines prohibit time-limited offers, package deals, and discount promotions on these treatments. Pricing is provided at consultation, after the prescriber has assessed the patient and decided on the indicated product class, the indicated dose, and the indicated zone. This is the framework the guidelines describe and the one we operate inside.

What the 2025 regulatory changes mean for your consultation

Two significant regulatory shifts apply to dermal filler treatment in Australia, and they both affect what you experience as a patient.

The September 2025 AHPRA cosmetic guidelines are the most consequential change to non-surgical cosmetic regulation in more than a decade. Every prescription for a cosmetic injectable now requires an in-person or video consultation between the prescriber and the patient before the prescription is written. Asynchronous prescribing — an online form filled out without a real-time conversation — is no longer acceptable practice. This closed the loophole that powered some of the worst cosmetic-injectable incidents of the 2010s.

Registered nurses must now have at least 12 months of full-time-equivalent post-registration nursing experience before performing cosmetic procedures, regardless of cosmetic-specific training. A new category of designated registered-nurse prescriber has been created for nurses with additional qualifications; outside that category, prescription rights remain with medical practitioners and nurse practitioners only.

Under-18 patients now have a mandatory seven-day cooling-off period between informed consent and any non-surgical cosmetic procedure. AHPRA’s guidance specifically describes the prescribing of filler to minors as “inappropriate” in almost all cases. Body dysmorphic disorder screening at consultation is now required, as is explicit discussion of risks and of alternative options including no treatment at all.

On the TGA side, advertising rules for cosmetic injectables tightened substantially in 2024 and were reinforced with further guidance in June 2025. Direct or indirect promotion of Schedule 4 prescription medicines to the consumer is prohibited; this includes generic-class terms used in promotional contexts, brand names, before-and-after images that imply a specific product, testimonials, and price-based inducements. The TGA established a Targeted Compliance Unit in April 2025 to enforce these rules, and the consumer advocacy report by Operation Redress in June 2025 found 98 of 100 Australian cosmetic clinic websites in apparent breach. Enforcement is real and active.

Cosmabl operates inside this framework. Every dermal filler treatment prescription booked through this platform is preceded by an in-person or video consultation with a prescriber who has personally reviewed the patient’s clinical history. Treatment is administered in the patient’s home by a Cosmabl registered nurse, with the prescription tied to the specific patient, the indicated zone, and the dose authorised at consultation. The product brand and batch number are recorded in the clinical record for traceability. The seven-day cooling-off pathway applies. The consent conversation includes risks, alternatives including no treatment, and an honest acknowledgement of what filler does and does not do.

How to choose a practitioner, and what to ask in consultation

The single most useful piece of consumer protection in Australian cosmetic medicine costs nothing, takes ninety seconds, and is almost never recommended in clinic marketing. Every registered health practitioner in Australia appears on the public AHPRA register at ahpra.gov.au. A search of the practitioner’s name returns their profession, division, registration status, and any conditions or undertakings on their practice. A patient should do this before the first appointment, not after a complication.

Beyond registration, the consultation itself does most of the diagnostic work on whether the practitioner is one to keep.

A useful first question is what the practitioner uses, when, and why. The answer should mention the product class — hyaluronic acid, calcium hydroxyapatite, or poly-L-lactic acid — and the reasoning that ties product choice to your specific zone and goal. A practitioner who recommends a non-reversible filler chemistry should be able to explain, unprompted, that this trade-off exists and what it means if you change your mind. A practitioner who treats all fillers as interchangeable is not thinking carefully enough.

A useful second question is what they would decline to do. A prescriber who has never declined a patient, who treats every request as a yes-by-default, is not selling restraint. Restraint is most of what good practice in this field looks like. Asking what the practitioner would say no to, and listening to whether the answer is concrete (“I would not place hyaluronic acid in the tear-trough on a patient with thin skin”, “I would not exceed two millilitres in a first-time lip patient”, “I would not treat someone within four weeks of dental surgery”) or a deflection, is more revealing than any credential.

A useful third question is what their vascular-occlusion protocol is. Every practitioner who places filler should be able to describe, calmly and immediately, what they would do if they thought an occlusion had occurred during your treatment. They should have hyaluronidase on the premises (for hyaluronic acid cases), have a written protocol, know which hospital they would send you to, and have a relationship with that facility. A practitioner who has not thought through this question is one who has not thought through what could go wrong in the worst case.

Reasonable additional questions include the practitioner’s own caseload, their training pathway, who their prescriber is (if not the same person), and how to reach the clinic if something feels wrong out of hours. A practitioner who answers these without flinching is the one to keep; one who deflects or replies in marketing language is telling you something useful.

When dermal filler is not the answer

Part of honest practice in this field is naming the cases where filler is not the right intervention. Patients new to cosmetic treatment in their forties or fifties sometimes arrive asking for filler to address static lines and skin laxity that filler cannot actually fix — the underlying changes are structural, dermal, and surgical, not volumetric. A good consultation in those cases reframes the goal and discusses skin-quality interventions, energy-based devices, or surgical options without dismissing the patient.

Patients with active inflammatory skin conditions, autoimmune disease flares, recent dental work, recent infection, or pregnancy and breastfeeding will usually have their treatment deferred rather than proceeded with. These are not absolute contraindications in every case, but they shift the risk calculation and the timing.

Patients with body dysmorphic disorder or significant body-image distress are not well served by cosmetic procedures, and the September 2025 guidelines specifically require screening for this at consultation. Saying no, kindly and clearly, is part of the practitioner’s job in those cases. A clinic willing to do this work is one that takes its medical responsibility seriously.

The conservative summary

Dermal filler is the most common cosmetic injectable category in Australia and one of the best-evidenced for routine use. The chemistry is well-characterised, the technique is well-described, the side-effect profile is broadly favourable, and the regulatory floor under the consultation has lifted substantially in 2025.

What is more variable, and what most clinic marketing leaves unspoken, is the practice around the product. In other words, the product choice, the volume per visit, and the interval between treatments. Other things to consider are willingness of the practitioner to decline a request that is not in your interest, the honesty about reversibility, particularly with non-hyaluronic-acid products, and the overall thoroughness of the consent conversation.

If you are considering dermal filler treatment for the first time, the most useful thing you can do is verify your practitioner on the AHPRA register, book a real consultation rather than a same-day appointment, ask the questions described above, and start conservatively. If you are already on an ongoing treatment plan, the same questions are worth asking your current practitioner at your next visit — particularly the question of whether you actually need treatment this year, given what the literature now shows about how long previous treatments persist. The conservative answer is rarely the most lucrative one for the clinic. It is, with very few exceptions, the right one for the patient.

References

AHPRA, Putting patients first: New guidelines for cosmetic procedures (2 September 2025). https://www.ahpra.gov.au/News/2025-09-02-New-guidelines-for-cosmetic-procedures.aspx

AHPRA, Performing non-surgical cosmetic procedures (guidelines hub). https://www.ahpra.gov.au/Resources/Cosmetic-surgery-hub/Cosmetic-procedure-guidelines.aspx

TGA, Referring to cosmetic injectables in advertising (updated guidance). https://www.tga.gov.au/news/media-releases/referring-cosmetic-injectables-advertising

TGA, Advertising health services and cosmetic injections: FAQs. https://www.tga.gov.au/products/regulations-all-products/advertising/specialised-advertising-issues-and-topics/advertising-health-services-and-cosmetic-injections-frequently-asked-questions-and-answers

TGA, Cosmetic injections guidance. https://www.tga.gov.au/cosmetic-injections

Master M, Azizeddin A, Master V. Hyaluronic Acid Filler Longevity in the Mid-face: A Review of 33 Magnetic Resonance Imaging Studies. Plastic and Reconstructive Surgery Global Open, July 2024. https://journals.lww.com/prsgo/fulltext/2024/07000/hyaluronic_acid_filler_longevity_in_the_mid_face_.36.aspx

de Castro Costa M et al. Clinical Durability of Hyaluronic Acid-Based Dermal Fillers for Facial Application: A Systematic Review. Aesthetic Plastic Surgery, 2025. https://pubmed.ncbi.nlm.nih.gov/41261256/

Chakhachiro A, Waseem M. Risk Factor Analysis for Vascular Occlusions After Dermal Filler Injections: A Systematic Review and Meta-Analysis. Cureus, April 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12097758/

Vascular Occlusion Following Dermal Filler Injections: A Systematic Review of Clinical Evidence and Emergency Management. 2025. https://www.mdpi.com/2673-6373/6/3/51

Efficacy and Safety of Hyaluronic Acid Lip Fillers: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Aesthetic Surgery Journal, 2025. https://pubmed.ncbi.nlm.nih.gov/41186199/

Serious Complications of Hyaluronic Acid Fillers: A Retrospective Study of 290,307 Cases. Plastic and Reconstructive Surgery, 2025. https://pubmed.ncbi.nlm.nih.gov/40358958/

Update on Blindness From Filler. PubMed, 2024. https://pubmed.ncbi.nlm.nih.gov/38630871/

Rzepniewski PT et al. Longevity of hyaluronic acid dermal fillers – current state of knowledge. Dermatology Review, 2024. https://www.termedia.pl/Journal/-56/pdf-54313-10

Facial Overfilled Syndrome. Journal of Cosmetic Dermatology, 2024. https://onlinelibrary.wiley.com/doi/10.1111/jocd.16244

AHPRA, Thinking about cosmetic injectables? Consumer factsheet. https://www.ahpra.gov.au/Resources/Cosmetic-surgery-hub/Information-for-the-public/Thinking-about-cosmetic-injectables.aspx

Operation Redress, Mass breaches of TGA advertising rules by cosmetic injectors (report), June 2025. https://www.opred.com.au/10/06/2025/mass-breaches-report

Important information

This article is provided for general educational purposes only and is not medical advice. It does not replace consultation with a registered medical practitioner. All cosmetic procedures carry risks. Outcomes vary between individuals. Suitability for any treatment is determined at a private consultation following clinical assessment, history-taking, and informed consent. If you are considering treatment, book a consultation with a registered medical practitioner.

This article does not constitute advertising of any prescription-only therapeutic good. Cosmabl does not name or recommend specific products in this article. Treatment selection is made at consultation by a registered medical practitioner based on your individual clinical assessment. All injectable cosmetic procedures carry risks including but not limited to bruising, swelling, infection, asymmetry, allergic reaction, and — rarely — vascular occlusion or other serious complications. Outcomes vary between individuals.

If you are considering this procedure, the next step is a private consultation with a registered medical practitioner. Suitability is decided at consultation based on your clinical history, examination, and goals. Cosmabl’s mandatory consultation-and-cooling-off pathway applies to all procedures. Pricing is provided at consultation; we do not advertise time-limited prices, discounts, or package deals.

Many cosmetic procedures, prescription medications, and active skincare ingredients are contraindicated or have insufficient safety data in pregnancy and breastfeeding. If you are pregnant, planning pregnancy, or breastfeeding, discuss any treatment, prescription, or active-ingredient skincare with your GP, obstetrician, or registered medical practitioner before use.

Cosmabl does not provide non-therapeutic cosmetic procedures to patients under the age of 18. Cosmetic procedures should be considered only after psychological, lifestyle, and non-procedural options have been explored. At consultation, our practitioners screen for body dysmorphic disorder and other conditions for which cosmetic procedures may not be the appropriate care pathway. If you are under 18, or if you are uncertain whether a cosmetic procedure is the right step for you, please speak with your GP first.

Cosmabl (Northern Beaches Aesthetics Pty Ltd). Editorial governance POL-EDIT-001 v1.0; per-article record TPL-EDIT-001 v1.0. This article complies with the AHPRA / Medical Board Cosmetic Procedures Guidelines (effective 2 September 2025), the Therapeutic Goods Advertising Code, and section 133 of the Health Practitioner Regulation National Law.

---

Hero photo by Gustavo Fring on Pexels